Heart Rhythm
Volume 6, Issue 6 , Pages 725-730 , June 2009

Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation

Received 10 December 2008 ,Accepted 18 February 2009.

References 

  1. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–666
  2. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation. 2000;102:2619–2628
  3. Oral H, Scharf C, Chugh A, et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation. 2003;108:2355–2360
  4. Verma A, Wazni OM, Marrouche NF, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol. 2005;45:285–292
  5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415
  6. Ono K, Tsujimoto G, Sakamoto A, et al. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature. 1994;370:301–304
  7. Duru F, Barton M, Lüscher TF, et al. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?. Cardiovasc Res. 2001;49:272–280
  8. Mackenzie L, Bootman MD, Laine M, et al. The role of inositol 1,4,5-trisphosphate receptors in Ca2+ signalling and the generation of arrhythmias in rat atrial myocytes. J Physiol. 2002;541:395–409
  9. Li X, Zima AV, Sheikh F, et al. Endothelin-1-induced arrhythmogenic Ca2+ signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate (IP3)-receptor type 2-deficient mice. Circ Res. 2005;96:1274–1281
  10. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434–2440
  11. Burrell KM, Molenaar P, Dawson PJ, et al. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther. 2000;292:449–459
  12. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation (A study in awake chronically instrumented goats). Circulation. 1995;92:1954–1968
  13. Lévy S, Camm AJ, Saksena S, et al. International consensus on nomenclature and classification of atrial fibrillation: a collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol. 2003;14:443–445
  14. Murray JA, Kennedy JW, Figley MM, et al. Quantitative angiocardiography: II. The normal left atrial volume in man. Circulation. 1968;37:800–804
  15. Mabuchi N, Tsutamoto T, Maeda K, et al. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J. 2000;64:765–777
  16. Wozakowska-Kapłon B, Opolski G. Concomitant recovery of atrial mechanical and endocrine function after cardioversion in patients with persistent atrial fibrillation. J Am Coll Cardiol. 2003;41:1716–1720
  17. Goette A, Hoffmanns P, Enayati W, et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol. 2001;88:906–909
  18. Tsutamoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427–1433
  19. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516
  20. Wada A, Tsutamoto T, Matsuda Y, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation. 1994;89:2232–2240
  21. Tsutamoto T, Wada A, Maeda K, et al. Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J. 1997;134:910–916
  22. Gerstenfeld EP, Dixit S, Callans D, et al. Utility of exit block for identifying electrical isolation of the pulmonary veins. J Cardiovasc Electrophysiol. 2002;13:971–979
  23. Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol. 2004;43:1004–1009
  24. Katritsis DG, Toumpoulis IK, Giazitzoglou E, et al. Latent arterial hypertension in apparently lone atrial fibrillation. J Interv Card Electrophysiol. 2005;13:203–207
  25. Yamada T, Murakami Y, Okada T, et al. Plasma brain natriuretic peptide level after radiofrequency catheter ablation of paroxysmal, persistent, and permanent atrial fibrillation. Europace. 2007;9:770–774
  26. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81:512–525
  27. Van Wagoner DR, Pond AL, Lamorgese M, et al. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res. 1999;85:428–436
  28. Redpath CJ, Rankin AC, Kane KA, et al. Anti-adrenergic effects of endothelin on human atrial action potentials are potentially anti-arrhythmic. J Mol Cell Cardiol. 2006;40:717–724
  29. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest. 1995;96:1059–1065
  30. van Wamel AJ, Ruwhof C, van der Valk-Kokshoom LE, et al. The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem. 2001;218:113–124
  31. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608–2614
  32. Hocini M, Jaïs P, Sanders P, et al. Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation. 2005;112:3688–3696
  33. O'Neill MD, Jaïs P, Takahashi Y, et al. The stepwise ablation approach for chronic atrial fibrillation—evidence for a cumulative effect. J Interv Card Electrophysiol. 2006;16:153–167

PII: S1547-5271(09)00209-4

doi: 10.1016/j.hrthm.2009.02.027

Heart Rhythm
Volume 6, Issue 6 , Pages 725-730 , June 2009

Article Tools

* Image Usage & Resolution